J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

A Dutch court ruled on Wednesday that billionaire and global vaccine proponent, Bill Gates, must stand trial in the ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

For anyone without insurance, you can find a free flu shot provider under the state Department of Health Services Vaccines ...

Elevated Capital Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 6.7% during the 3rd ...

Stanley Laman Group Ltd. cut its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.2% in the 3rd quarter, Holdings ...